Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 5, Pages 1244
Publisher
MDPI AG
Online
2020-05-15
DOI
10.3390/cancers12051244
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
- (2019) Yahya Ashraf et al. Journal for ImmunoTherapy of Cancer
- Mesenchymal stem cell homing towards cancer cells is increased by enzyme activity of cathepsin D
- (2019) Gowthami Vangala et al. EXPERIMENTAL CELL RESEARCH
- Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
- (2019) Shristi Bhattarai et al. Cancers
- Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value
- (2019) Federica Miglietta et al. ONCOLOGIST
- Cathepsin D non-proteolytically induces proliferation and migration in human omental microvascular endothelial cells via activation of the ERK1/2 and PI3K/AKT pathways
- (2018) Md Zahidul I. Pranjol et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Androgen blockade based clinical trials landscape in triple negative breast cancer
- (2018) Yaqin Shi et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers
- (2018) Séverine Guiu et al. BRITISH JOURNAL OF CANCER
- The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome
- (2018) Carmela Ricciardelli et al. CLINICAL CANCER RESEARCH
- Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
- (2018) Tiffany A. Traina et al. JOURNAL OF CLINICAL ONCOLOGY
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- THE PROTEASE-DEPENDENT MESENCHYMAL MIGRATION OF TUMOR-ASSOCIATED MACROPHAGES AS A TARGET IN CANCER IMMUNOTHERAPY
- (2018) Philippe Gui et al. Cancer Immunology Research
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Macrophage Polarization: Anti-Cancer Strategies to Target Tumor-Associated Macrophage in Breast Cancer
- (2017) Muhammad Tariq et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature
- (2017) Xixi Zhao et al. Oncotarget
- A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
- (2016) H. Bonnefoi et al. ANNALS OF ONCOLOGY
- p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading
- (2016) Emanuela Guerra et al. BMC CANCER
- The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
- (2016) Ivana Bozovic-Spasojevic et al. CLINICAL CANCER RESEARCH
- Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells
- (2016) Francesco Caiazza et al. ENDOCRINE-RELATED CANCER
- Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis
- (2016) Changjun Wang et al. Oncotarget
- Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin
- (2016) Anna R. Kwilas et al. Oncotarget
- Cathepsin D as an indicator of clinical outcome in early breast carcinoma during the first 3 years of follow-up
- (2013) Milan Markićević et al. Biomarkers in Medicine
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
- (2013) A. Gucalp et al. CLINICAL CANCER RESEARCH
- A Prognostic Model for Triple-Negative Breast Cancer Patients Based on Node Status, Cathepsin-D and Ki-67 Index
- (2013) Liang Huang et al. PLoS One
- The Impact of Androgen Receptor Expression on Breast Cancer Survival: A Retrospective Study and Meta-Analysis
- (2013) Qing Qu et al. PLoS One
- Androgen receptor in triple negative breast cancer
- (2012) K.M. McNamara et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- TGF-β-induced epithelial-mesenchymal transition: A link between cancer and inflammation
- (2012) Jonas Fuxe et al. SEMINARS IN CANCER BIOLOGY
- Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1
- (2011) Jessica L L Robinson et al. EMBO JOURNAL
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- The prognostic importance of cathepsin D and E-cadherin in early breast cancer: A single-institution experience
- (2011) GALIA JACOBSON-RABER et al. Oncology Letters
- Epstein-Barr virus as a marker of biological aggressiveness in breast cancer
- (2010) C Mazouni et al. BRITISH JOURNAL OF CANCER
- Pro-cathepsin D interacts with the extracellular domain of the chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth
- (2010) M. Beaujouin et al. JOURNAL OF CELL SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now